Submitted by dcc on Thu, 2017-02-16 13:44 Study Title: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV MelanomaCIRB: Adult CIRB - Late Phase EmphasisLead Group: ECOG-ACRINStatus: ActiveReview Status: Available to Open
